Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial

Authors

Alejandro Castillo Mondragón (ORCID: https://orcid.org/0009-0003-8469-2760)
Christine Dobek
Yanqi Li (ORCID: https://orcid.org/0000-0002-1437-9301)
Mark Kowalski (ORCID: https://orcid.org/0000-0001-9590-6259)
James Helliwell
Claire Prener Miller (ORCID: https://orcid.org/0000-0003-3874-8201)
Helene Rovsing
Amanda Malone
Asger Reinstrup Bihlet (ORCID: https://orcid.org/0000-0002-6944-1731)
Vik Peck
Lee S. Simon (ORCID: https://orcid.org/0000-0001-5673-807X)
Mike Wilmink
Kathrine Moriat
Philip G. Conaghan (ORCID: https://orcid.org/0000-0002-3478-5665)
S. L. Boll

Institutions

University of Leeds (GB)
Herlev Hospital (DK)
Vejle Sygehus (DK)
Phoenix (United States) (US)
NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
Aurinia (Canada) (CA)
Newton Energy Group (United States) (US)

Publication Details

Journal: The Lancet Rheumatology
Published: 2024-10-11
DOI: https://doi.org/10.1016/s2665-9913(24)00223-6
Citations: 5
Primary Topic: Osteoarthritis Treatment and Mechanisms
Type: article
Field-Weighted Citation Impact: 2.35

Funders

National Institute for Health and Care Research
Leeds Biomedical Research Centre

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial

Alejandro Castillo Mondragón, Christine Dobek, Yanqi Li, Mark Kowalski et al.

Oct 11, 2024

5 citations

The Lancet Rheumatology

Osteoarthritis Treatment and Mechanisms

2.35

article

Efficacy and safety of a diffusion-based extended-release fluticasone propionate intra-articular injection (EP-104IAR) in knee osteoarthritis (SPRINGBOARD): a 24-week, multicentre, randomised, double-blind, vehicle-controlled, phase 2 trial

Alejandro Castillo Mondragón, Christine Dobek, Yanqi Li, Mark Kowalski, James Helliwell, Claire Prener Miller, Helene Rovsing, Amanda Malone, Asger Reinstrup Bihlet, Vik Peck, Lee S. Simon, Mike Wilmink, Kathrine Moriat, Philip G. Conaghan, S. L. Boll

October 11, 2024article en

5 citations

Abstract

No abstract available for this paper.

The Lancet RheumatologyVol. 6(12)

University of Leeds (GB), Herlev Hospital (DK), Vejle Sygehus (DK), Phoenix (United States) (US), NIHR Leeds Musculoskeletal Biomedical Research Unit (GB), Aurinia (Canada) (CA), Newton Energy Group (United States) (US)

National Institute for Health and Care Research, Leeds Biomedical Research Centre

Good health and well-being

Openalex Percentile: Top 11%

Osteoarthritis Treatment and Mechanisms

2.35

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.